Drugs / COVID-19 Vaccine
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04889274 | May 2021 → Apr 2026 overdue | cardiovascular disorder | Queen Mary University of London | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06683352 | Nov 2024 → Jul 2025 | COVID-19, influenza | BioNTech SE | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04977024 | Sep 2021 → Dec 2026 expected | COVID-19, leukemia, plasma cell myeloma | GeoVax, Inc. | Active not recruiting | Missed primary |
| Phase 43 trials | ||||||
| Phase 4 | NCT05107557 | Nov → Dec 2021 | COVID-19 | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT05104333 | Nov 2021 → Nov 2022 | pneumonia | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT05012800 | Jul 2021 → Aug 2022 | — | Beijing 302 Hospital | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06116669 | Nov 2023 → Dec 2024 | iron deficiency anemia | Swiss Federal Institute of Technology | Unknown | No outcome recorded |
| — | NCT05019456 | Mar 2021 → Dec 2025 overdue | COVID-19, influenza | University of Arizona | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06178991 Comparator | Dec 2023 → Nov 2024 | COVID-19, influenza | BioNTech SE | Completed | Mixed |
| Phase 3 | NCT05415267 Comparator | Jul 2023 → Dec 2026 expected | COVID-19 | Kirby Institute | Recruiting | No outcome recorded |
Press releases naming this drug 205 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Covid-19 vaccine | “The COVID-19 vaccine was manufactured by Sinovac Research” NCT05107557 ↗ |
| Known as | COVID-19 vaccine (Vero cell), Inactivated | “This study is a randomized and controlled Phase IV clinical trial of the COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Research” NCT05107557 ↗ |
| Modality | Vaccine | “COVID-19 vaccine” NCT04889274 ↗ |
| Route | Intramuscular | “Patients receive one dose of SOC mRNA SARS-CoV-2 vaccine IM in the upper arm on days 0 and 28.” NCT04977024 ↗ |